A Dark Vector Cognition product

Item 5. Other Information

4K characters. Original on sec.gov ·

Item 5. Other Information

The 1 table in Item 5. Other Information as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

Rule 10b5-1 Trading Plans

Our policy governing transactions in our securities by our directors, officers, and employees permits our officers,

directors and employees to enter into trading plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934,

as amended. The following table describes the written plans for the sale of our securities adopted by our directors and officers

(as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934) during the third quarter of 2026, each of which is

intended to satisfy the affirmative defense conditions of Rule 10b5-1 (each, a “Trading Plan”). Other than as described in the

table below, none of our directors or officers adopted, modified or terminated a Trading Plan in the third quarter of 2026.

Name and TitleDate of Adoption of Trading PlanScheduled Expiration Date of Trading Plan (1)Maximum Shares Subject to Trading Plan
Kristen Ambrose SVP, Chief Accounting Officer8/06/20264/30/20275,422(2)
Sangeeta Bhatia Director8/13/20267/30/20271,189
Carmen Bozic EVP, Global Medicines Development and Medical Affairs, and Chief Medical Officer8/06/20267/30/202716,915(2)
Alan Garber Director8/27/20267/30/20275,320
Reshma Kewalramani Chief Executive Officer and President, Director8/5/202612/1/202747,800
Jeffrey Leiden Executive Chairman8/5/202611/4/202718,411
Joy Liu EVP, Chief Legal Officer8/21/20265/3/202720,764(2)
Bruce Sachs Director8/26/20267/20/20279,888
Nancy Thornberry Director8/15/20267/30/20272,571
Charles F. Wagner, Jr. EVP, Chief Operating & Financial Officer8/10/20267/30/202715,286
(1) A Trading Plan may expire on an earlier date if all contemplated transactions are completed before such Trading Plan’s expiration date, upon termination by broker or the holder of the Trading Plan, or as otherwise provided in the Trading Plan.
(2) The maximum shares listed has not been reduced by the number of shares of common stock that will be withheld to satisfy tax withholding obligations at future vesting dates because such number of shares is not yet determinable.

Principal Accounting Officer

On October 30, 2026, the Company appointed Jonathan Oppenheim, our Vice President, Corporate Controller, as our

principal accounting officer, effective on February 15, 2027 (the “Effective Date”). On the Effective Date, Kristen Ambrose

will be appointed Senior Vice President, Global Business Operations and Transformation and will cease serving as our

principal accounting officer.

Jonathan Oppenheim, 56, has been our Vice President, Corporate Controller since August 2020. Mr. Oppenheim

previously served as Controller, US Business Unit at Takeda Pharmaceutical Company, a global biopharmaceutical company,

from January 2019 to August 2020. Prior to that, he served as Senior Director, Assistant Corporate Controller at Shire plc, a

biotechnology company, from November 2015 to January 2019, and Director, Technical Accounting at Thermo Fisher

Scientific Inc., a life sciences and clinical research company, from May 2010 to November 2015. Mr. Oppenheim received

his B.S. in Accounting from the University of Massachusetts Dartmouth and is a Certified Public Accountant.

There are no transactions involving the Company and Mr. Oppenheim that the Company would be required to report

pursuant to Item 404(a) of Regulation S-K. There is no arrangement or understanding between Mr. Oppenheim and any other

person pursuant to which Mr. Oppenheim was appointed as principal accounting officer.

Previous: Item 1A. Risk Factors · Next: Item 6. Exhibits